| Followers | 232 |
| Posts | 26887 |
| Boards Moderated | 0 |
| Alias Born | 01/12/2013 |
Wednesday, April 10, 2013 3:27:20 PM
Zip
Thanks. However, Lacri-lube eye ointment "contains white soft paraffin, liquid paraffin (also known as mineral oil) and lanolin alcohols (also known as wool alcohols). These ingredients produce a transparent, lubricating and moistening film on the surface of the eyeball."
Mineral oil Is a light mixtures of alkanes in the C15 to C40 range.
"EPA-lube" is not painful on the sclera even at 100% concentration. It does need to be cut otherwise you will have haze from the mixture of oil and normal 0.9% NaCl tear mixture.
Still don't try this at home, I'm professionally educated and skilled to recognize and treat reactions/infections
-----------
My experience: left eye one gtt with a few 0.9 normal saline gtts after to clear "oil" vision
1) 100% must be cut with 0.9% Normal Saline
2) PlusEPA is somewhat oxidized...smells like fish, although when I injest PO I don't have fish Eructation
3) clears nasolacrimal duct within minutes, you can smell and taste oil
4) seems to have cleared left nasal passage also
5) throughout the day no irritation, no redness, no oily vision
6) left eye has felt significantly more lubricated over day, especially noted outside
Plan to take 5 days off and watch for s/s of Longer term reactions then repeat again.
This is NOT advisable to try.
Thanks. However, Lacri-lube eye ointment "contains white soft paraffin, liquid paraffin (also known as mineral oil) and lanolin alcohols (also known as wool alcohols). These ingredients produce a transparent, lubricating and moistening film on the surface of the eyeball."
Mineral oil Is a light mixtures of alkanes in the C15 to C40 range.
"EPA-lube" is not painful on the sclera even at 100% concentration. It does need to be cut otherwise you will have haze from the mixture of oil and normal 0.9% NaCl tear mixture.
Still don't try this at home, I'm professionally educated and skilled to recognize and treat reactions/infections
-----------
My experience: left eye one gtt with a few 0.9 normal saline gtts after to clear "oil" vision
1) 100% must be cut with 0.9% Normal Saline
2) PlusEPA is somewhat oxidized...smells like fish, although when I injest PO I don't have fish Eructation
3) clears nasolacrimal duct within minutes, you can smell and taste oil
4) seems to have cleared left nasal passage also
5) throughout the day no irritation, no redness, no oily vision
6) left eye has felt significantly more lubricated over day, especially noted outside
Plan to take 5 days off and watch for s/s of Longer term reactions then repeat again.
This is NOT advisable to try.
Recent AMRN News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:10 PM
